Brief: Daewoong Releases Positive Phase 3 Topline Results For New Antidiabetic Drug
25/01/2022 14:41
Jan 25 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL RELEASED POSITIVE PHASE 3 TOPLINE
RESULTS FOR NEW ANTIDIABETIC DRUG
* DAEWOONG PHARMA - EXPECTING TO ROLL OUT NEW KEY DRUG FOR
DIABETES ENAVOGLIFLOZIN NEXT YEAR AS A SINGLE DRUG AND A
COMBINATION DRUG
Source text for Eikon: ID:nPn8ZZ5T6a
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier